NEW YORK: A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca Plc’s US$1bil deal to acquire closely-held Amolyt Pharma illustrates, the likelihood is there’s much more to come.
Original article here
